NCT01564017已完成2 期
Phase II, Multicenter, Randomized, Double-blind Study, With Subcutaneous Immunotherapy, in Parallel Groups and Placebo-controlled, in Patients With Rhinoconjunctivitis ± Asthma Sensitized to Dermatophagoides Pteronyssinus.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 150
- 试验地点
- 24
- 主要终点
- Changes in nasal provocation test
研究概览
简要总结
As part of the registration plan of our products and after performing a Phase I study the present trial has been designed to compare the efficacy of 5 different doses of subcutaneous immunotherapy in depot presentation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must sign the Informed Consent Form.
- •Patients must be between 18 and 60 years of age.
- •Patients with perennial allergic rhinoconjunctivitis produced by Dermatophagoides pteronyssinus during at least 2 years prior to participating in the study. Although the pathology being studied is allergic rhinoconjunctivitis, patients who have concomitant mild or moderate asthma may be included.
- •Patients who have had a skin prick test result greater or equal to 3 mm in diameter against Dermatophagoides pteronyssinus.
- •Patients who have specific Immunoglobulin E (IgE) greater or equal to class 2 (CAP/PHADIA) to Dermatophagoides pteronyssinus.
- •Patients will preferably be monosensitized to Dermatophagoides pteronyssinus. Polysensitized patients may only be included in the study if their other sensitizations are produced by:
- •Pollens whose season period does not overlap with the study treatment or, if overlap, whose specific IgE levels are less than class
- •Perennial allergens with specific IgE levels less than class
- •Allergens that do not cohabit with the patient or whose environmental levels are not high enough to produce symptoms during the study period.
- •Women of child-bearing potential must have a negative urine pregnancy test at the time they begin the study.
- •Furthermore, women of child-bearing potential must agree to use adequate contraceptive methods during this study if they are sexually active.
排除标准
- •Patients with stable and continued use of medication to treat their allergic condition during the 2 weeks prior to their inclusion in the study.
- •Patients sensitized and with specific IgE levels greater or equal to class 2 to other perennial or seasonal allergens clinically relevant including other mites unless they are cross reactive with Dermatophagoides pteronyssinus.
- •Patients who have received immunotherapy in the 5 years prior to the study against either the allergen being tested or an allergen which is cross-reactive, or who are currently receiving immunotherapy for any other allergen.
- •Patients with severe asthma or FEV1< 70% or with asthma which requires treatment with inhaled or systemic corticoids at the time of the study or in the 8 weeks immediately prior to the onset of treatment.
- •Patients with immunological, cardiac, renal or hepatic diseases or with any other illness which the investigators deem may interfere with the study.
- •Patients with a prior history of anaphylaxis.
- •Patients with chronic urticaria.
- •Patients with moderate-severe atopic dermatitis.
- •Patients with clinically relevant malformations of the upper respiratory tract.
- •Patients who have participated in another clinical trial within 3 months prior to this study.
- •Patients being treated with tricyclic antidepressants, psychotropic drugs, beta-blockers, or angiotensin-converting enzyme inhibitors (ACEIs).
- •Women who are pregnant or breast-feeding or are of child-bearing age and who do not agree to use adequate contraception if they are sexually active and who have not demonstrated that they have been surgically sterilized or have other means of not bearing children.
- •Patients who cannot attend study visits.
- •Patients who are uncooperative or refuse to participate in the study.
结局指标
主要结局
Changes in nasal provocation test
时间窗: from baseline (V0) to final visit (VF 18 weeks after randmization)
Variation of the concentration of DPT extract needed to produce a positive nasal provocation test from baseline (V0) to final visit (FV). The changes will be compared among groups (including the placebo group).
次要结局
未报告次要终点
研究者
研究点 (24)
Loading locations...
相似试验
进行中（未招募）
1 期
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's LymphomaNon-Hodgkin LymphomaNCT05950165Cho Pharma Inc.37
已完成
1 期
Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell CarcinomaAdvanced Renal Cell CarcinomaNCT01513187Spanish Oncology Genito-Urinary Group53
已完成
1 期
RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic CancerMetastatic Pancreatic CancerNCT03189914Processa Pharmaceuticals46
进行中（未招募）
1 期
Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.SARS-CoV-2 InfectionCOVID-19NCT05490108Shanghai Zerun Biotechnology Co.,Ltd60
终止
1 期
Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)Small Cell Lung Cancer and Breast CancerNCT03773133Ipsen9